The debate between stakeholders about the tournament’s financial model is continuing even as it packs stadiums and makes good money
Must Read
AstraZeneca to buy EsoBiotec for up to $1 billion
Drugmaker AstraZeneca said on Monday it will buy biotechnology firm EsoBiotec for up to $1 billion.
EsoBiotec’s Engineered NanoBody Lentiviral (ENaBL) platform can genetically modify...